Cell Biotech Co., Ltd. (KOSDAQ:049960)
South Korea · Delayed Price · Currency is KRW 16,330
-570 (-3.37%)
At close: Jun 5, 2026
Cell Biotech Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 56,494 | 53,126 | 49,913 | 53,787 | 50,526 | 46,873 |
Other Revenue | - | -0 | - | - | -0 | - |
| 56,494 | 53,126 | 49,913 | 53,787 | 50,526 | 46,873 | |
Revenue Growth (YoY) | 17.44% | 6.44% | -7.20% | 6.46% | 7.79% | 2.83% |
Cost of Revenue | 15,473 | 14,770 | 14,102 | 15,139 | 12,854 | 11,399 |
Gross Profit | 41,021 | 38,356 | 35,811 | 38,649 | 37,672 | 35,475 |
Selling, General & Admin | 24,842 | 23,931 | 21,847 | 29,845 | 25,278 | 21,988 |
Research & Development | 3,850 | 3,883 | 4,332 | 3,725 | 3,559 | 3,500 |
Amortization of Goodwill & Intangibles | 222.82 | 246.23 | 313.06 | 307.11 | 236.59 | 293.61 |
Other Operating Expenses | 187.19 | 216.36 | 226.87 | 221.45 | 249.55 | 207.87 |
Operating Expenses | 31,282 | 30,442 | 29,015 | 36,453 | 31,621 | 28,218 |
Operating Income | 9,739 | 7,914 | 6,796 | 2,195 | 6,051 | 7,257 |
Interest Expense | -26.18 | -32.59 | -60.88 | -61.95 | -37.49 | -42.48 |
Interest & Investment Income | 2,741 | 2,778 | 3,112 | 3,180 | 860.17 | 1,103 |
Earnings From Equity Investments | - | - | - | -82.2 | - | - |
Currency Exchange Gain (Loss) | 2,365 | -385.52 | 5,093 | 698.5 | 2,990 | 3,325 |
Other Non Operating Income (Expenses) | 205.16 | 219.48 | 84.34 | 1,162 | 309.01 | 306.97 |
EBT Excluding Unusual Items | 15,024 | 10,493 | 15,024 | 7,092 | 10,173 | 11,950 |
Gain (Loss) on Sale of Investments | 584 | 868.86 | 575.56 | -211.19 | - | 111.68 |
Gain (Loss) on Sale of Assets | -138.43 | -108.08 | 10.14 | -0.26 | -0.91 | 29.05 |
Pretax Income | 15,469 | 11,254 | 15,610 | 6,880 | 10,172 | 12,090 |
Income Tax Expense | 2,062 | 1,129 | 483.01 | 576.36 | 1,891 | 1,707 |
Net Income | 13,407 | 10,125 | 15,127 | 6,304 | 8,281 | 10,383 |
Net Income to Common | 13,407 | 10,125 | 15,127 | 6,304 | 8,281 | 10,383 |
Net Income Growth | -3.79% | -33.06% | 139.97% | -23.87% | -20.25% | 225.58% |
Shares Outstanding (Basic) | 7 | 7 | 7 | 7 | 7 | 7 |
Shares Outstanding (Diluted) | 7 | 7 | 7 | 7 | 7 | 7 |
Shares Change (YoY) | -0.08% | -0.01% | 0.01% | -0.73% | -2.50% | -0.32% |
EPS (Basic) | 1959.71 | 1479.45 | 2210.00 | 921.07 | 1201.04 | 1468.32 |
EPS (Diluted) | 1959.71 | 1479.45 | 2210.00 | 921.00 | 1201.00 | 1468.00 |
EPS Growth | -3.71% | -33.06% | 139.96% | -23.31% | -18.19% | 226.54% |
Free Cash Flow | 5,975 | 8,004 | 18,138 | 6,264 | 10,445 | 14,044 |
Free Cash Flow Per Share | 873.42 | 1169.58 | 2649.95 | 915.24 | 1515.03 | 1985.94 |
Dividend Per Share | - | - | - | 450.000 | 450.000 | 450.000 |
Gross Margin | 72.61% | 72.20% | 71.75% | 71.85% | 74.56% | 75.68% |
Operating Margin | 17.24% | 14.90% | 13.62% | 4.08% | 11.98% | 15.48% |
Profit Margin | 23.73% | 19.06% | 30.31% | 11.72% | 16.39% | 22.15% |
Free Cash Flow Margin | 10.58% | 15.07% | 36.34% | 11.65% | 20.67% | 29.96% |
EBITDA | 13,335 | 11,528 | 10,668 | 6,100 | 9,689 | 11,046 |
EBITDA Margin | 23.61% | 21.70% | 21.37% | 11.34% | 19.18% | 23.57% |
D&A For EBITDA | 3,597 | 3,614 | 3,872 | 3,904 | 3,638 | 3,789 |
EBIT | 9,739 | 7,914 | 6,796 | 2,195 | 6,051 | 7,257 |
EBIT Margin | 17.24% | 14.90% | 13.62% | 4.08% | 11.98% | 15.48% |
Effective Tax Rate | 13.33% | 10.03% | 3.09% | 8.38% | 18.59% | 14.12% |
Advertising Expenses | - | 7,975 | 5,249 | 11,977 | 9,134 | 6,632 |